Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
The Vanguard Group filed Amendment No. 7 to a Schedule 13G/A reporting that it beneficially owns 0 shares of Kiniksa Pharmaceuticals International Plc common stock, representing 0% of the class. The filing states an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report separately. The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Kiniksa Pharmaceuticals International, plc Chief Financial Officer Mark Ragosa exercised stock options and sold shares in a planned transaction. On March 9, 2026, he exercised options covering 36,722 Class A Ordinary Shares at exercise prices between $17.76 and $26.74 per share. The same day, he sold 17,981 shares at $45.58 per share and 18,741 shares at $46.24 per share in open‑market transactions. These sales, totaling 36,722 shares, were carried out under a pre‑arranged Rule 10b5‑1 trading plan executed on August 14, 2025. Following the transactions, Ragosa directly owned 12,086 Class A Ordinary Shares.
Kiniksa Pharmaceuticals Ltd. submitted a Rule 144 notice reporting proposed sale of Class A ordinary shares related to an Employee Stock Option Exercise dated 03/09/2026. The filing lists 36,722 shares in the securities-to-be-sold row and discloses prior sales by Mark Ragosa of 12,000 shares on 01/08/2026 and 17,845 shares on 02/09/2026, with corresponding proceeds of $502,628.00 and $772,311.00.
FMR LLC reports beneficial ownership in Kiniksa Pharmaceuticals International plc Class A common stock. The filing shows FMR LLC (and Abigail P. Johnson in related capacity) beneficially owns 4,854,354.23 shares, equal to 10.6% of the class as reported with a 02/27/2026 reference. The cover lists sole voting power of 4,852,623 shares and sole dispositive power of 4,854,354.23 shares. The schedule includes an Exhibit 99 13d-1(k)(1) agreement and signatures by an authorized representative on 03/05/2026.
Kiniksa Pharmaceuticals International, plc Chief Medical Officer John F. Paolini exercised options and sold shares of Class A Ordinary Shares. He exercised a fully vested option for 40,000 Share Options at an exercise price of $10.36 per share, acquiring 40,000 Class A Ordinary Shares on March 2, 2026. That same day, he sold a total of 40,000 Class A Ordinary Shares in open-market transactions at weighted average prices ranging from about $43.555 to $46.09, under a Rule 10b5-1 plan executed on November 18, 2025. After these transactions, he directly holds 61,324 Class A Ordinary Shares and 58,424 Share Options.
Kiniksa Pharmaceuticals, Ltd. submitted a Rule 144 notice reporting the sale of 40,000 Class A ordinary shares on 03/02/2026. The transaction is described as an employee stock option exercise settled as a broker payment for a cashless exercise through Charles Schwab & Co., Inc..
Kiniksa Pharmaceuticals International, plc reports its annual business overview, highlighting a commercial rare-disease franchise and a focused cardiovascular pipeline. The company markets ARCALYST, an IL‑1α/IL‑1β cytokine trap, as the first and only FDA‑approved therapy for recurrent pericarditis, targeting an estimated 40,000 treated patients in the United States.
Kiniksa is advancing KPL‑387, an IL‑1 receptor monoclonal antibody with FDA Orphan Drug Designation for pericarditis, through a Phase 2/3 recurrent pericarditis program, with Phase 2 data expected in the second half of 2026. Preclinical KPL‑1161 aims for quarterly dosing, while development of abiprubart in Sjögren’s Disease has been discontinued as the company explores strategic options for the asset.
The business model combines internal development with partnerships. Kiniksa evenly splits ARCALYST profits and certain proceeds with Regeneron, has out‑licensed vixarelimab to Genentech with potential milestones and royalties, and granted Huadong rights to ARCALYST in a broad Asia‑Pacific territory. Intellectual property protection extends across composition, methods of use and formulations, supplemented by U.S. and EU regulatory exclusivities.
Kiniksa Pharmaceuticals International, plc reported a strong turnaround in 2025, moving to profitability on rapid ARCALYST growth. Net product revenue reached $202.1 million in the fourth quarter and $677.6 million for the year, a 62% increase driven by adoption in recurrent pericarditis.
The company generated 2025 net income of $59.0 million, or $0.80 per basic share, compared with a net loss of $43.2 million in 2024. Total 2025 revenue was $677.6 million against operating expenses of $600.3 million, leading to income from operations of $77.2 million.
Kiniksa ended 2025 with $414.1 million in cash, cash equivalents, and short-term investments, up $170.4 million year over year. Management expects ARCALYST 2026 net product revenue of $900–$920 million and highlighted pipeline milestones, including Phase 2 KPL-387 data expected in the second half of 2026 and a planned Phase 1 start for KPL-1161 by the end of 2026.
Kiniksa Pharmaceuticals International, plc received an updated ownership disclosure showing that investment adviser Rubric Capital Management LP and David Rosen together report beneficial ownership of 3,328,653 Class A ordinary shares, representing 7.37% of the class, based on 45,161,019 shares outstanding as of October 24, 2025.
The reporting parties indicate they have shared voting and dispositive power over these shares, which are held through funds they advise, including Rubric Capital Master Fund LP. They certify the position is held in the ordinary course of business and not with the purpose or effect of changing or influencing control of Kiniksa.
Kiniksa Pharmaceuticals International, plc director Quart Barry D reported option exercises and share sales in February 2026 under a pre‑arranged Rule 10b5‑1 trading plan executed on September 11, 2025.
On February 10 and February 12, Barry exercised share options at an exercise price of $15.47 per Class A ordinary share and immediately sold the resulting shares in open-market transactions at $45 per share. Across both dates, 2,800 Class A ordinary shares were sold while maintaining 12,546 Class A ordinary shares held directly after the reported transactions. The options involved were fully vested and exercisable.